Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BXLT's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

BXLT Guru Trades in

BXLT Guru Trades in

Q2 2016

BXLT Guru Trades in Q2 2016

Martin Whitman 464,033 sh (unchged)
Mario Gabelli Sold Out
John Buckingham Sold Out
Jeremy Grantham Sold Out
Jeff Auxier Sold Out
Paul Tudor Jones Sold Out
Jim Simons Sold Out
Mairs and Power Sold Out
Manning & Napier Advisors, Inc Sold Out
Eric Mindich Sold Out
Pioneer Investments Sold Out
Paul Singer Sold Out
Murray Stahl Sold Out
Daniel Loeb Sold Out
George Soros Sold Out
Keeley Asset Management Corp Sold Out
Tweedy Browne Sold Out
First Eagle Investment Sold Out
Joel Greenblatt Sold Out
Richard Pzena Sold Out
Third Avenue Management Sold Out
Steve Mandel Sold Out
John Paulson Sold Out
Tweedy Browne Global Value Sold Out
» More
2016

BXLT Guru Trades in 2016

Martin Whitman Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with BXLT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology  
Compare:NAS:ALXN, XKRX:068270, NAS:VRTX, XKRX:207940, NAS:REGN, NAS:INCY, XMCE:GRF.P, OCSE:NZYM B, NAS:BMRN, LSE:SHP, SZSE:002252, XBRU:UCB, HKSE:01177, NAS:ALNY, ASX:CSL, OCSE:GEN, NAS:NKTR, NAS:EXEL, NAS:ALKS, NAS:BLUE » details
Traded in other countries:9BX.Germany, BXLT.Mexico,
Headquarter Location:USA
Baxalta Inc is engaged in the developing and marketing of biopharmaceuticals. The Company offers biopharmaceuticals for the treatment of hemophilia, bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, and other chronic.

Baxalta Inc was incorporated on September 8, 2016. It is a biopharmaceutical company engaged in the field of unmet medical needs covering various diseases which includes haemophilia, immunology and oncology. The Company develops, manufactures and markets a diverse portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions, as well as oncology treatments for acute lymphoblastic leukemia. It also invests in emerging technology platforms, including gene therapy and biosimilars. Its competitors include Advate, Feiba, Gammagard. The Company is subject to rules and regulations put forth by the jurisdiction it operates in.

Guru Investment Theses on Baxalta Inc

Third Avenue Management Comments on Baxalta - Mar 29, 2016

We initiated a position in Baxalta, a biopharmaceutical company, in the prior quarter. The company was the target of a takeover bid from Shire during this most recent quarter. Under the agreement, Baxalta (NYSE:BXLT) shareholders will receive $18.00 in cash and 0.1482 Shire ADS for each Baxalta share. Based on Shire’s closing price, this represented a value of $45.57 per Baxalta share, resulting in an unrealized IRR of 26.0%. We are pleased that another party found Baxalta’s assets as interesting as we did. The Fund has owned NVIDIA shares since 2012. The company has done a good job building value over the years. Demand for its graphics processing units (GPUs) has grown, driven by growth in gaming along with more computer-intensive applications such as professional graphics, automotive and artificial intelligence. We exited the position during the quarter for valuation reasons, realizing an IRR of 35.4%, and redeployed the proceeds into other investments.



From the Third Avenue Value Fund 1st quarter 2016 letter.



Check out Martin Whitman latest stock trades

Keeley Funds Comments on Baxalta Inc. - Feb 03, 2016

The Fund’s second best performer was Baxalta, Inc. (NYSE:BXLT) which climbed over 23 percent and added 68 basis points of return to the Fund during the quarter. The spin-off from Baxter rebounded nicely during the quarter and shares were boosted on takeover speculation. A bid from rival Shire came late in the quarter and we anticipate the share to move closer to that takeover bid in the coming months.



From the Keeley All Cap Value Fund 4th quarter 2015 shareholder letter.



Check out John Keeley latest stock trades

Top Ranked Articles about Baxalta Inc

5 Companies Reach 52-Week Highs Exelon, Baxalta, Home Depot, Cigna, Stanley Black & Decker achieve milestones
According to GuruFocus' list, these stocks have reached their 52-week highs. Read more...

Ratios

vs
industry
vs
history

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.46
BXLT's Dividend Yield % is ranked lower than
77% of the 240 Companies
in the Global Biotechnology industry.

( Industry Median: 1.24 vs. BXLT: 0.46 )
Ranked among companies with meaningful Dividend Yield % only.
BXLT' s Dividend Yield % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0.46
Current: 0.46
0
0.46
Dividend Payout Ratio 0.18
BXLT's Dividend Payout Ratio is ranked higher than
89% of the 133 Companies
in the Global Biotechnology industry.

( Industry Median: 0.39 vs. BXLT: 0.18 )
Ranked among companies with meaningful Dividend Payout Ratio only.
BXLT' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0.18
Current: 0.18
0
0.18
Forward Dividend Yield % 0.61
BXLT's Forward Dividend Yield % is ranked lower than
74% of the 224 Companies
in the Global Biotechnology industry.

( Industry Median: 1.25 vs. BXLT: 0.61 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.46
BXLT's 5-Year Yield-on-Cost % is ranked lower than
81% of the 305 Companies
in the Global Biotechnology industry.

( Industry Median: 1.61 vs. BXLT: 0.46 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
BXLT' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0.46
Current: 0.46
0
0.46

Valuation & Return

vs
industry
vs
history

More Statistics

Revenue (TTM) (Mil) $6,335.00
EPS (TTM) $ 1.21
Short Percentage of Float1.38%
52-Week Range $29.83 - 46.52
Shares Outstanding (Mil)683.54

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 6,653 7,364 7,990
EPS ($) 2.27 2.64 2.93
EPS without NRI ($) 2.27 2.64 2.93
EPS Growth Rate
(Future 3Y To 5Y Estimate)
2.32%
Dividends per Share ($) 0.32 0.33 0.36

Piotroski F-Score Details

Piotroski F-Score: ----
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}